Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin

Exclusion Criteria

• •1. Patients who have used lipid-lowering agents other than statin or ezetimibe within the last 3 months
• •2. A serum triglyceride on fasting \>400 mg/dL
• •3. A history of muscular symptoms or rhabdomyolysis due to the use of statin
• •4. Hypersensitivity to rosuvastatin or ezetimibe
• •5. Labeled contraindications to rosuvastatin or rosuvastatin Severe renal impairment (CrCl \<30 mL/min by Cockcroft-Gault formula or estimated GFR \<30 mL/min / 1.73 m2 by MDRD equation) ALT, AST ≥3 × ULN or active liver disease CPK ≥3 × ULN
• •6. Enrollment of other clinical trials within 30 days
• •7. Any other issues that the treating physician assumes ineligible for participation in the trial